Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent a revolutionary approach in the treatment of type 2 diabetes
Exclusion criteria: (1) Patients with abnormal coagulation function [limits: prothrombin time (PT) between 1014 seconds, activated partial thromboplastin time (APTT) between 2540 seconds, and fibrinogen (Fib) levels between 2.04.0 g/L] and immunodeficiency [either primary immunodeficiency (congenital or hereditary conditions leading to impaired immune responses) or secondary immunodeficiency (conditions acquired through HIV infection, chronic immunosuppressive therapy, or severe malnutrition)]
The short version: they're based on a real study but the headline is the best case, not the typical result
Instead of jumping from 0.5mg to 1.0mg, you could try 0.75mg for 2 to 4 weeks
Change in appetite could primarily be due to the drugs association with increased levels of serotonin and peptides, which are necessary hormones responsible for controlling the feeling of hunger or fullness, and contributes towards better control of eating behaviors
mito-TEMPO nitroxide radical concentration was obtained by double integration followed by Spin Count module (Bruker) and expressed as the nitroxide radical per g of protein